NCT02548052 - Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2015

Primary Completion Date

February 19, 2016

Study Completion Date

February 19, 2016

Conditions

Psoriasis

Interventions

DRUG

GSK2981278 0.03%

GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.

DRUG

GSK2981278 0.1%

GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.

DRUG

GSK2981278 0.8%

GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.

DRUG

GSK2981278 4%

GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.

DRUG

Vehicle

GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.

DRUG

Betamethasone valerate 0.1%

Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.

Trial Locations (1)

20095

GSK Investigational Site, Hamburg